Dr. med. Christian Pohlkampfrom 08.06.2020Identifying resistance mutations in targeted therapies
Over the past few years, the use of targeted therapies has proven effective for various forms of hematological neoplasia, and increasingly become routine. The rational molecular design of such active substances allows for the targeted blocking of intracellular signal chains in malignant cells, resulting e.g. in cell cycle arrest or ideally apoptosis. Unfortunately, resistance occurs even against such tailored therapies.
Dr. rer. nat. Constance Bärfrom 18.02.2020Assessing Sequence Variants
Sequencing technologies have developed rapidly in the last few years. It is possible to sequence an entire genome or a larger panel within just a few days. At the MLL, data from the sequencing machine is loaded to our private cloud in real time and automatically preprocessed using the very latest algorithms.
Dr. rer. nat. Sabine Jerominfrom 16.11.2019Standardization of the BCR-ABL1 Quantification in CML
When using molecular tests to quantify BCR-ABL1 in CML patients, it is recommended that the test be performed in a standardized laboratory. Standardization ensures that results comply with the ELN (European LeukemiaNet; Baccarani et al., Blood 2013) guidelines, enables comparisons to be made between laboratories and serves as quality assurance.
from 05.11.2019Immunophenotyping in multiple myeloma: Patients without minimal residual disease live longer
The prognostic significance of minimal residual disease (MRD) in patients with multiple myeloma has been examined in numerous studies and is the subject of much controversial discussion. Existing data has to date been extremely heterogeneous with regard to patient collectives, therapies, number of cases, and the methodology via which MRD was detected.
from 01.11.2019Additional molecular genetic diagnostics for multiple myeloma
Approx. 10% of all hematological neoplasias are plasma cell diseases such as multiple myeloma (MM) or plasma cell leukemias. As is the case for other hematological diseases, molecular genetic diagnostics can be viewed as increasingly relevant in the diagnosis, prognosis and therapeutic stratification of MM.
Dr. med. Christian Pohlkampfrom 30.10.2019Munich Leukemia Laboratory MLL offers integrated findings for myelodysplastic syndromes
After the successful introduction of Integrated Findings for acute myeloid leukemia (AML) at the end of 2017, Münchner Leukämielabor GmbH (MLL) now also offers a version for myelodysplastic syndromes (MDS). The goal here is also to provide both a clear summary and detailed interpretation of the often complex constellation of individual cytomorphological, flow cytometry, and in particular cytogenetic and molecular genetic findings.
Dr. med. Christian Pohlkampfrom 28.10.2019Step-by-step diagnosis at MLL
Cost-conscious diagnostics are a must. As MLL hematologists who, in general, have invariably spent a lot of time working in hospitals and outpatient clinics, we are particularly aware of this problem. It has thus always been our priority to provide you and your patients with a cost-effective procedure in the form of step-by-step diagnostics.
Dr. rer. nat. Ines Schmidtsfrom 23.10.2019The importance of advanced molecular diagnostics in cytopenia and (suspected) MDS
Next-generation sequencing (NGS) has rapidly become an indispensable tool in diagnostic molecular genetics. A recent article in Blood (Steensma Blood 2018) examined how patients with ambiguous cytopenia or with a (suspected) MDS diagnosis can benefit from the diagnostic potential of NGS.
Dr. rer. nat. Ines Schmidtsfrom 17.10.2019The importance of next-generation sequencing (NGS) diagnostics in (suspected) acute myeloid leukemia (AML)
In the last issue (1/2019), MLL News featured an article which was recently published in Blood on the use of high-throughput sequencing in (unclear) cytopenia and MDS (Steensma et al. 2018). Next-generation sequencing (NGS) is already playing a major role in AML diagnostics today and will continue to become more and more important.